Akoya Biosciences, Inc. announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode?? Signature Panels and preliminary data from the Thermo Fisher ViewRNA assays on Akoya's platforms. Industry-leading capabilities of the company's spatial biology platforms will be presented during Akoya's Spotlight Theater, titled "Spatial Biology 2.0: Spatial Insights and Precision Medicine at Unpre unprecedented Scale" on April 8 at 3 PM (PST).

The event will describe how researchers are revealing new insights into the tumor microenvironment, elucidating the mechanisms of cancer treatment response, and paving the way for spatial biology to impact patient outcomes. Deployment of Akoya's PhenoCycler®?-Fusion 2.0, PhenoImager®? HT 2.0, and PhenoCode Panels across the research continuum, from ultrahigh-plex discoveries to actionable signatures, will be described by the presenters: Suzanne K. Coberly, MS MD, FCAP, Scientific Senior Director, Discovery & Translational Pathology, Oncogenesis TRC, Bristol Myers Squibb, Arutha Kulasinghe PhD, Scientific Director of the Queensland Spatial Biology Center in Brisbane, Group Leader at The University of Queensland, Pascal Bamford, PhD, Senior Vice President, R&D and Laboratory Operations, Akoya Biosciences.